

RNF139 antibody - N-terminal region
Rabbit Polyclonal Antibody
Catalog # AI12216**Specification**

RNF139 antibody - N-terminal region - Product Information

Application	WB
Primary Accession	Q8WU17
Other Accession	NM_007218 , NP_009149
Reactivity	Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog
Predicted	Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	76kDa KDa

RNF139 antibody - N-terminal region - Additional Information**Gene ID** 11236**Alias Symbol** **HRCA1, MGC31961, RCA1, TRC8****Other Names**

E3 ubiquitin-protein ligase RNF139, 6.3.2.-, RING finger protein 139, Translocation in renal carcinoma on chromosome 8 protein, RNF139 ([HGNC:17023](http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=17023))

Format

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage

Add 50 ul of distilled water. Final anti-RNF139 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

Precautions

RNF139 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

RNF139 antibody - N-terminal region - Protein Information**Name** RNF139 ([HGNC:17023](#))**Function**

E3-ubiquitin ligase; acts as a negative regulator of cell proliferation through mechanisms involving G2/M arrest and cell death (PubMed: [10500182](http://www.uniprot.org/citations/10500182), PubMed: [12032852](http://www.uniprot.org/citations/12032852), PubMed: [17016439](http://www.uniprot.org/citations/17016439))

target="_blank">17016439). Required for MHC class I ubiquitination in cells expressing the cytomegalovirus protein US2 before dislocation from the endoplasmic reticulum (ER) (PubMed:19720873). Affects SREBP processing by hindering the SREBP-SCAP complex translocation from the ER to the Golgi, thereby reducing SREBF2 target gene expression (PubMed:19706601, PubMed:20068067). Involved in the sterol-accelerated degradation of HMGCR (PubMed:22143767, PubMed:23223569). This is achieved through binding of RNF139 to INSIG1 and/or INSIG2 at the ER membrane (PubMed:22143767). In addition, interaction of RNF139 with AUP1 facilitates interaction of RNF139 with ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase AMFR, leading to ubiquitination of HMGCR (PubMed:23223569). The ubiquitinated HMGCR is then released from the ER into the cytosol for subsequent destruction (PubMed:22143767, PubMed:23223569). Required for INSIG1 ubiquitination (PubMed:20068067). May be required for EIF3 complex ubiquitination (PubMed:20068067).

Cellular Location

Endoplasmic reticulum membrane; Multi-pass membrane protein

Tissue Location


Highly expressed in testis, placenta and adrenal gland. Moderate expression in heart, brain, liver, skeletal muscle and pancreas, and low expression in lung and kidney


RNF139 antibody - N-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

RNF139 antibody - N-terminal region - Images





WB Suggested Anti-RNF139 Antibody Titration: 0.2-1 $\mu\text{g/ml}$

ELISA Titer: 1:312500

Positive Control: MCF7 cell lysate

RNF139 is supported by BioGPS gene expression data to be expressed in MCF7